Cargando…

Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation

PURPOSE: To investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China. MATERIALS AND METHODS: We retrospectively...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tao, Lv, Zheng, Feng, Huayi, Li, Jinlong, Cui, Bo, Yang, Yang, Huang, Xing, Zhang, Xiangyi, Li, Xintao, Ma, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133414/
https://www.ncbi.nlm.nih.gov/pubmed/35646691
http://dx.doi.org/10.3389/fonc.2022.860133
_version_ 1784713561405128704
author Wang, Tao
Lv, Zheng
Feng, Huayi
Li, Jinlong
Cui, Bo
Yang, Yang
Huang, Xing
Zhang, Xiangyi
Li, Xintao
Ma, Xin
author_facet Wang, Tao
Lv, Zheng
Feng, Huayi
Li, Jinlong
Cui, Bo
Yang, Yang
Huang, Xing
Zhang, Xiangyi
Li, Xintao
Ma, Xin
author_sort Wang, Tao
collection PubMed
description PURPOSE: To investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China. MATERIALS AND METHODS: We retrospectively analyzed cases with non-distant metastases (≤ T4M0). Of 106 patients, 30 (28.3%), 40 (37.7%), and 36 (34.0%) met the criteria for UrAC, primary BAC, and UCGD, respectively. Data on patient demographics, tumor pathology, and survival outcomes were collected. The median follow-up was 36 months. Survival was analyzed using multivariate Cox regression. RESULTS: Patients with UrAC were younger (51.87 ± 15.25 years) than those with primary BAC (60.50 ± 12.56 years) and UCGD (63.83 ± 11.60 years) (P<0.001). Patients with UrAC were the most likely to be stage T3–4 (70.0% vs. 40.0% vs. 44.4%; P<0.001), while the primary BAC group had a higher rate of poor differentiation than the UrAC and UCGD groups (57.4% vs. 18.5% vs. 24.1%; P<0.001). The Kaplan–Meier curves showed that the overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) of the primary BAC group were poorer than those of both the UrAC and UCGD groups (P=0.0046,P<0.0001,P=0.0077 respectively). Regarding BAC, patients with mucinous adenocarcinoma tended to have better OS and PFS than those with other histological types (P<0.005,P=0.0245). Multivariate Cox regression analysis revealed that tumor type (P=0.002), T stage (P=0.034), and the age-adjusted Charlson Comorbidity Index (aCCI) scores (P=0.005) predicted the postoperative OS and DSS of the patients. For PFS, the tumor type (P=0.011), grade (P=0.000), and aCCI (P=0.002) scores were predictive. CONCLUSION: Among UrAC, primary BAC, and UCGD patients, the prognosis was poorest for those with primary BAC. Attempts should be made to diagnose these aggressive tumors early, since patients in whom tumors are detected early appear to survive longer.
format Online
Article
Text
id pubmed-9133414
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91334142022-05-27 Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation Wang, Tao Lv, Zheng Feng, Huayi Li, Jinlong Cui, Bo Yang, Yang Huang, Xing Zhang, Xiangyi Li, Xintao Ma, Xin Front Oncol Oncology PURPOSE: To investigate the significance of demographic and pathological characteristics on the survival outcomes of urachal adenocarcinoma (UrAC), primary bladder adenocarcinoma (BAC) and urothelial carcinoma with glandular differentiation (UCGD) in China. MATERIALS AND METHODS: We retrospectively analyzed cases with non-distant metastases (≤ T4M0). Of 106 patients, 30 (28.3%), 40 (37.7%), and 36 (34.0%) met the criteria for UrAC, primary BAC, and UCGD, respectively. Data on patient demographics, tumor pathology, and survival outcomes were collected. The median follow-up was 36 months. Survival was analyzed using multivariate Cox regression. RESULTS: Patients with UrAC were younger (51.87 ± 15.25 years) than those with primary BAC (60.50 ± 12.56 years) and UCGD (63.83 ± 11.60 years) (P<0.001). Patients with UrAC were the most likely to be stage T3–4 (70.0% vs. 40.0% vs. 44.4%; P<0.001), while the primary BAC group had a higher rate of poor differentiation than the UrAC and UCGD groups (57.4% vs. 18.5% vs. 24.1%; P<0.001). The Kaplan–Meier curves showed that the overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) of the primary BAC group were poorer than those of both the UrAC and UCGD groups (P=0.0046,P<0.0001,P=0.0077 respectively). Regarding BAC, patients with mucinous adenocarcinoma tended to have better OS and PFS than those with other histological types (P<0.005,P=0.0245). Multivariate Cox regression analysis revealed that tumor type (P=0.002), T stage (P=0.034), and the age-adjusted Charlson Comorbidity Index (aCCI) scores (P=0.005) predicted the postoperative OS and DSS of the patients. For PFS, the tumor type (P=0.011), grade (P=0.000), and aCCI (P=0.002) scores were predictive. CONCLUSION: Among UrAC, primary BAC, and UCGD patients, the prognosis was poorest for those with primary BAC. Attempts should be made to diagnose these aggressive tumors early, since patients in whom tumors are detected early appear to survive longer. Frontiers Media S.A. 2022-05-12 /pmc/articles/PMC9133414/ /pubmed/35646691 http://dx.doi.org/10.3389/fonc.2022.860133 Text en Copyright © 2022 Wang, Lv, Feng, Li, Cui, Yang, Huang, Zhang, Li and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Tao
Lv, Zheng
Feng, Huayi
Li, Jinlong
Cui, Bo
Yang, Yang
Huang, Xing
Zhang, Xiangyi
Li, Xintao
Ma, Xin
Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
title Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
title_full Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
title_fullStr Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
title_full_unstemmed Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
title_short Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
title_sort survival of patients with urac and primary bac and urothelial carcinoma with glandular differentiation
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133414/
https://www.ncbi.nlm.nih.gov/pubmed/35646691
http://dx.doi.org/10.3389/fonc.2022.860133
work_keys_str_mv AT wangtao survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT lvzheng survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT fenghuayi survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT lijinlong survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT cuibo survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT yangyang survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT huangxing survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT zhangxiangyi survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT lixintao survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation
AT maxin survivalofpatientswithuracandprimarybacandurothelialcarcinomawithglandulardifferentiation